| 1 | Allergic contact dermatitis | FING00000068 | 59.18 |
| 2 | CXCL16 levels | GCST90468928 | 55.04 |
| 3 | FCRL6 levels | GCST90469209 | 54.06 |
| 4 | CXCL9 levels | GCST90468935 | 52.24 |
| 5 | Psoriatic arthritis | GCST90243956 | 51.28 |
| 6 | Psoriasis vulgaris (PheCode 696.41) | GCST90476190 | 50.54 |
| 7 | GZMA/GZMH ratio | GCST90315008 | 49.46 |
| 8 | Nasal polyp | FING00000858 | 48.78 |
| 9 | CD160/KLRB1 ratio | GCST90313731 | 48.67 |
| 10 | Multiple sclerosis | GCST90475833 | 48.58 |
| 11 | TNFRSF8 levels | GCST90470915 | 48.46 |
| 12 | IL15 levels | GCST90469556 | 47.60 |
| 13 | Psoriasis (PheCode 696.4) | GCST90476187 | 47.08 |
| 14 | Psoriasis and related disorder (PheCode 696) | GCST90476186 | 46.59 |
| 15 | GNLY/GZMA ratio | GCST90314949 | 45.37 |
| 16 | CRTAM/FCRL6 ratio | GCST90314274 | 45.31 |
| 17 | RPE levels | GCST90470495 | 44.95 |
| 18 | GNLY levels | GCST90469372 | 44.62 |
| 19 | TXNL1 levels | GCST90470993 | 44.34 |
| 20 | Lymphocyte count | GCST90025984 | 44.29 |
| 21 | Type 1 diabetes | GCST90000529 | 44.27 |
| 22 | GZMH levels | GCST90469425 | 44.22 |
| 23 | PAFAH1B3 levels | GCST90470145 | 43.71 |
| 24 | Lymphoid neoplasms (B-cell phenocluster) | GCST90624736 | 43.66 |
| 25 | MS-disease / Multiple Sclerosis | FING00000839 | 43.65 |
| 26 | CD244/CRTAM ratio | GCST90313763 | 43.64 |
| 27 | CD160/NCR1 ratio | GCST90313732 | 42.82 |
| 28 | CRTAM/VCAM1 ratio | GCST90314281 | 41.97 |
| 29 | Lymphocyte count | GCST90018742 | 41.25 |
| 30 | Second line medication for Crohn's disease | FING00001284 | 41.06 |
| 31 | CD160/CXCL16 ratio | GCST90313728 | 40.88 |
| 32 | Lymphoid neoplasms (somatic mutation group 2 phenocluster) | GCST90624750 | 40.41 |
| 33 | RBFOX3 levels | GCST90470432 | 40.30 |
| 34 | IL18 levels | GCST90428411 | 40.07 |
| 35 | Chronic sinusitis | FING00000298 | 40.01 |
| 36 | Prescriptions - tramadol | opioid analgesic,selective serotonin re-uptake inhibitor,norepinephrine re-uptake inhibitor | UKBB00000706 | 40.00 |
| 37 | Prescriptions - opioid analgesic|selective serotonin re-uptake inhibitor|norepinephrine re-uptake inhibitor | UKBB00000694 | 40.00 |
| 38 | CD48/CRTAM ratio | GCST90313839 | 39.87 |
| 39 | GZMA/LTA ratio | GCST90315012 | 39.59 |
| 40 | Left-hemisphere dorsal attention network to amygdala white-matter structural connectivity | GCST90302706 | 39.54 |
| 41 | Psoriasis | GCST90019016 | 39.44 |
| 42 | GZMA/GZMB ratio | GCST90315007 | 39.37 |
| 43 | Lymphocyte count | GCST90002317 | 39.31 |
| 44 | IFNG levels | GCST90469515 | 39.20 |
| 45 | lymphocyte (absolute count, mean, inv-norm transformed) | GCST90475426 | 38.43 |
| 46 | Reimbursement for rheumatic diseases | FING00001247 | 38.27 |
| 47 | Asthma-related infections | FING00000118 | 37.73 |
| 48 | LTA levels | GCST90469813 | 37.40 |
| 49 | CCL17/PDGFB ratio | GCST90313688 | 37.31 |
| 50 | Type 1 diabetes | GCST90013791 | 37.26 |
| 51 | lymphocyte (absolute count, maximum, inv-norm transformed) | GCST90475423 | 37.00 |
| 52 | lymphocyte (absolute count, minimum, inv-norm transformed) | GCST90475429 | 36.99 |
| 53 | ITGAL levels | GCST90469637 | 36.84 |
| 54 | Papulosquamous disorders | FING00001144 | 36.63 |
| 55 | NCR1 levels | GCST90470009 | 36.29 |
| 56 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475444 | 35.67 |
| 57 | Atopic dermatitis | FING00000125 | 35.53 |
| 58 | Dermatitis and eczema | FING00000402 | 35.44 |
| 59 | HLAE/IL15 ratio | GCST90315061 | 35.35 |
| 60 | IDO1 levels | GCST90469506 | 34.98 |
| 61 | SNRPB2 levels | GCST90470697 | 34.93 |
| 62 | Pain type(s) experienced in last month - Pain all over the body | Pain | UKBB00000632 | 34.89 |
| 63 | Asthma | GCST90468112 | 34.77 |
| 64 | LAT/LYN ratio | GCST90315283 | 34.74 |
| 65 | Lymphoid neoplasms (drug group 1 phenocluster) | GCST90624740 | 34.66 |
| 66 | APRT levels | GCST90468345 | 34.36 |
| 67 | Pulmonary fibrosis | GCST90018688 | 34.01 |
| 68 | IL2RB levels | GCST90469586 | 33.91 |
| 69 | Lymphoid neoplasms | GCST90624743 | 33.87 |
| 70 | Rheumatoid arthritis | GCST90132223 | 33.84 |
| 71 | Rheumatoid arthritis | FING00001267 | 33.79 |
| 72 | Asthma | respiratory | UKBB00000054 | 33.41 |
| 73 | GZMH/KLRD1 ratio | GCST90315016 | 33.13 |
| 74 | BOLA2 or BOLA2B levels | GCST90468460 | 32.92 |
| 75 | Autoimmune diseases excluding thyroid diseases | FING00000132 | 32.72 |
| 76 | Asthma-related acute respiratory infections | FING00000117 | 32.63 |
| 77 | Thyroid peroxidase antibody positivity in pregnancy | GCST90435202 | 32.58 |
| 78 | Asthma | Chronic lower respiratory diseases | UKBB00000053 | 32.50 |
| 79 | HSIL lesion of the cervix uteri | FING00000624 | 32.33 |
| 80 | EGFL7 levels | GCST90469083 | 32.14 |
| 81 | Rash and other nonspecific skin eruption (PheCode 687.1) | GCST90476167 | 31.93 |
| 82 | CD8A levels | GCST90468655 | 31.89 |
| 83 | Lymphocyte count | Blood count | UKBB00000411 | 31.79 |
| 84 | GZMA/TNFRSF8 ratio | GCST90315014 | 31.52 |
| 85 | Allergy/adverse effect of penicillin | injuries & poisonings | UKBB00000028 | 31.47 |
| 86 | Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications | GCST90093113 | 31.27 |
| 87 | eosinophil (absolute count, maximum, inv-norm transformed) | GCST90475288 | 31.11 |
| 88 | eosinophil (absolute count, mean, inv-norm transformed) | GCST90475291 | 31.09 |
| 89 | Lymphocyte count (UKB data field 30120) | GCST90468082 | 31.03 |
| 90 | Lymphocyte count | GCST90002388 | 31.03 |
| 91 | Personal history of allergy to drugs, medicaments and biologocal substances | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000641 | 30.88 |
| 92 | Psoriasis | FING00001222 | 30.79 |
| 93 | IL15/NCR1 ratio | GCST90315150 | 30.77 |
| 94 | Lymphocyte count | GCST90002316 | 30.70 |
| 95 | CD5/TNFRSF9 ratio | GCST90313862 | 30.67 |
| 96 | KIR3DL1 levels | GCST90469687 | 30.60 |
| 97 | GZMB/IL15 ratio | GCST90315015 | 30.57 |
| 98 | Eosinophill count | Blood count | UKBB00000206 | 30.56 |
| 99 | ACYP1 levels | GCST90468214 | 30.54 |
| 100 | Asthma (adult onset) | GCST007799 | 30.48 |
| 101 | Psoriasis | GCST90468147 | 30.46 |
| 102 | Eosinophil count | GCST004606 | 30.32 |
| 103 | Lymphocyte count | GCST004627 | 30.28 |
| 104 | CD160 levels | GCST90468599 | 30.12 |
| 105 | Diseases of hair and hair follicles (PheCode 704) | GCST90476209 | 29.98 |
| 106 | eosinophil (absolute count, minimum, inv-norm transformed) | GCST90475294 | 29.98 |
| 107 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Asthma | Medical conditions | UKBB00000098 | 29.92 |
| 108 | FCRL6/GZMA ratio | GCST90314806 | 29.39 |
| 109 | eosinophil (fraction, maximum, inv-norm transformed) | GCST90475297 | 29.15 |
| 110 | Asthma | GCST010042 | 28.95 |
| 111 | Poisoning by antibiotics | injuries & poisonings | UKBB00000653 | 28.90 |
| 112 | CD48/FCRL6 ratio | GCST90313840 | 28.87 |
| 113 | Neutrophil percentage of granulocytes | GCST004623 | 28.82 |
| 114 | Seropositive rheumatoid arthritis, wide | FING00001298 | 28.80 |
| 115 | Principal component-derived dietary pattern 26 | GCST90133031 | 28.78 |
| 116 | KDM3A levels | GCST90469671 | 28.77 |
| 117 | Sum eosinophil basophil counts | GCST004624 | 28.66 |
| 118 | CXCL10 levels | GCST90468923 | 28.64 |
| 119 | Asthma/COPD (KELA code 203) | FING00000121 | 28.61 |
| 120 | Mouth/teeth dental problems - Mouth ulcers | Mouth | UKBB00000488 | 28.59 |
| 121 | IL15/IL18BP ratio | GCST90315148 | 28.30 |
| 122 | Suggestive for eosinophilic asthma | FING00001344 | 28.23 |
| 123 | First line medication for Crohn's disease | FING00000544 | 28.21 |
| 124 | Atopic dermatitis | GCST90027161 | 28.19 |
| 125 | eosinophil (fraction, minimum, inv-norm transformed) | GCST90475303 | 28.16 |
| 126 | Chronic lymphocytic leukemia | GCST90624738 | 28.13 |
| 127 | GBP1 levels | GCST90469311 | 28.10 |
| 128 | lymphocyte (fraction, maximum, inv-norm transformed) | GCST90475432 | 28.05 |
| 129 | Eosinophill percentage (UKB data field 30210) | GCST90468069 | 27.90 |
| 130 | GZMA/TNFRSF4 ratio | GCST90315013 | 27.85 |
| 131 | Eosinophil percentage of granulocytes | GCST004617 | 27.84 |
| 132 | S100A11/S100A12 ratio | GCST90315798 | 27.79 |
| 133 | Disorders of orbit | FING00000449 | 27.78 |
| 134 | Plasma ascorbic acid 2-sulfate levels in chronic kidney disease | GCST90264832 | 27.74 |
| 135 | ARHGAP30 levels | GCST90468354 | 27.70 |
| 136 | Ulcerative rectosigmoiditis | FING00001394 | 27.64 |
| 137 | Chronic dermatitis due to solar radiation (PheCode 938.2) | GCST90476288 | 27.61 |
| 138 | TBCA levels | GCST90470812 | 27.59 |
| 139 | Autoimmune diseases | FING00000131 | 27.57 |
| 140 | Rheumatoid arthritis | GCST90132224 | 27.56 |
| 141 | IL2RA/NCR1 ratio | GCST90315161 | 27.55 |
| 142 | Seborrhoeic dermatitis | FING00001282 | 27.38 |
| 143 | KLRB1 levels | GCST90469709 | 27.37 |
| 144 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - None of the above | Medical conditions | UKBB00000101 | 27.35 |
| 145 | Graves disease, strict definition | FING00000592 | 27.26 |
| 146 | Eosinophil percentage of white cells | GCST004600 | 27.18 |
| 147 | Type1 diabetes, definitions combined, early onset | FING00001384 | 27.16 |
| 148 | Sarcoidosis | GCST90503483 | 27.11 |
| 149 | CD7 levels | GCST90468649 | 27.08 |
| 150 | Avoided activities or situations because of previous stressful experience in past month | Traumatic events | UKBB00000083 | 26.95 |
| 151 | CRTAM levels | GCST90468871 | 26.71 |
| 152 | Non-cancer illness code, self-reported - asthma | Medical conditions | UKBB00000506 | 26.71 |
| 153 | Asthma (childhood onset) | GCST007800 | 26.69 |
| 154 | CD244/FCRL6 ratio | GCST90313765 | 26.65 |
| 155 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Hayfever, allergic rhinitis or eczema | Medical conditions | UKBB00000100 | 26.60 |
| 156 | Blood cell traits latent factor 3 (white cell) | GCST90559245 | 26.56 |
| 157 | Respiratory disease (confirmatory factor analysis Factor 11) | GCST90309345 | 26.55 |
| 158 | VEGFB levels | GCST90471035 | 26.52 |
| 159 | Eosinophill percentage | Blood count | UKBB00000207 | 26.51 |
| 160 | Lymphoid leukemia, chronic (PheCode 204.12) | GCST90475613 | 26.50 |
| 161 | Thyroid peroxidase antibody levels in pregnancy | GCST90435201 | 26.25 |
| 162 | Seropositive rheumatoid arthritis, strict definition | FING00001297 | 26.23 |
| 163 | Systemic lupus erythematosus | GCST90011866 | 26.23 |
| 164 | Chronic lower respiratory diseases | FING00000290 | 26.22 |
| 165 | Seronegative rheumatoid arthritis | FING00001296 | 26.21 |
| 166 | Hyperthyroidism | GCST90468136 | 26.10 |
| 167 | SMNDC1 levels | GCST90470681 | 25.94 |
| 168 | Lichen ruber planus, wide definition including periferal and oral lichen planus | FING00000722 | 25.91 |
| 169 | CRTAM/GZMA ratio | GCST90314275 | 25.90 |
| 170 | TALDO1 levels | GCST90470802 | 25.86 |
| 171 | IPCEF1/SERPINE1 ratio | GCST90315184 | 25.84 |
| 172 | KIR2DL3 levels | GCST90469685 | 25.76 |
| 173 | CRTAM/LY9 ratio | GCST90314278 | 25.73 |
| 174 | Asthma (only as main-diagnosis) (more control exclusions) | FING00000114 | 25.63 |
| 175 | Asthma | GCST90014325 | 25.63 |
| 176 | DNAJC21 levels | GCST90469016 | 25.57 |
| 177 | GZMB levels | GCST90469424 | 25.55 |
| 178 | Non-cancer illness code, self-reported - hypothyroidism/myxoedema | Medical conditions | UKBB00000518 | 25.41 |
| 179 | AKT1S1/FHIT ratio | GCST90313228 | 25.36 |
| 180 | lymphocyte (fraction, mean, inv-norm transformed) | GCST90475435 | 25.32 |
| 181 | CD8 on Effector Memory CD8+ T cell | GCST90002056 | 25.32 |
| 182 | FCRL6/KLRD1 ratio | GCST90314807 | 25.31 |
| 183 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475448 | 25.30 |
| 184 | CD5 levels | GCST90468641 | 25.23 |
| 185 | Lymphocyte percentage | Blood count | UKBB00000412 | 25.22 |
| 186 | Smoking status (weighted GWA) | GCST90267303 | 25.21 |
| 187 | DKK1/IPCEF1 ratio | GCST90314471 | 25.12 |
| 188 | Hypothyroidism NOS (PheCode 244.4) | GCST90475653 | 25.11 |
| 189 | Psoriasis vulgaris | FING00001224 | 25.02 |
| 190 | eosinophil (fraction, mean, inv-norm transformed) | GCST90475300 | 24.93 |
| 191 | Other demyelinating diseases of the central nervous system | FING00000995 | 24.92 |
| 192 | Hypothyroidism, strict autoimmune | FING00000656 | 24.91 |
| 193 | Hypothyroidism | GCST90204167 | 24.90 |
| 194 | TNFRSF17 levels | GCST90470908 | 24.85 |
| 195 | PPM1B levels | GCST90470296 | 24.80 |
| 196 | EDAR/EGF ratio | GCST90314573 | 24.79 |
| 197 | DTI TBSS MD Superior corona radiata L | GCST90384597 | 24.73 |
| 198 | lymphocyte (fraction, minimum, inv-norm transformed) | GCST90475438 | 24.70 |
| 199 | Hypothyroidism | GCST90468138 | 24.68 |
| 200 | Eosinophil count | GCST90002298 | 24.63 |
| 201 | HSIL lesion of the cervix uteri, vagina or vulva | FING00000625 | 24.62 |
| 202 | INSR levels | GCST90469623 | 24.57 |
| 203 | Disorders of the thyroid gland | FING00000463 | 24.54 |
| 204 | Cerebrospinal fluid methylmalonate (MMA) levels | GCST90318243 | 24.54 |
| 205 | Other hypothyroidism | Disorders of thyroid gland | UKBB00000611 | 24.51 |
| 206 | Eosinophil percentage of white cells | GCST90002382 | 24.48 |
| 207 | Eosinophil count | GCST90002381 | 24.34 |
| 208 | Eosinophill count (UKB data field 30150) | GCST90468068 | 24.30 |
| 209 | Hypothyroidism | endocrine/metabolic | UKBB00000335 | 24.24 |
| 210 | Treatment/medication code - levothyroxine sodium | Medications | UKBB00000849 | 24.06 |
| 211 | Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers) | FING00000756 | 23.99 |
| 212 | Childhood asthma (age<16) (more control exclusions) | FING00000270 | 23.97 |
| 213 | Juvenile rheumatoid arthirtis | FING00000706 | 23.82 |
| 214 | Hypothyroidism NOS | endocrine/metabolic | UKBB00000336 | 23.73 |
| 215 | Type 1 diabetes | GCST90014023 | 23.71 |
| 216 | Mosaic chromosomal alteration of the X chromosome | GCST90165287 | 23.69 |
| 217 | Idiopathic pulmonary fibrosis | FING00000659 | 23.69 |
| 218 | Lymphocyte percentage of white cells | GCST90002389 | 23.68 |
| 219 | Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044) | GCST90042535 | 23.67 |
| 220 | PALM2 levels | GCST90470152 | 23.56 |
| 221 | Lymphocyte percentage (UKB data field 30180) | GCST90468083 | 23.56 |
| 222 | Blood cell traits latent factor 9 (white cell) | GCST90559251 | 23.54 |
| 223 | Asthma with exacerbation (PheCode 495.2) | GCST90476025 | 23.50 |
| 224 | MZB1 levels | GCST90469987 | 23.48 |
| 225 | Polyarthropathies | FING00001180 | 23.47 |
| 226 | Thyroid peroxidase antibody positivity with euthyroid in pregnancy | GCST90435203 | 23.46 |
| 227 | NBN levels | GCST90470002 | 23.39 |
| 228 | Hypothyroidism (PheCode 244) | GCST90475647 | 23.38 |
| 229 | Iridocyclitis | FING00000696 | 23.22 |
| 230 | CRTAM/ICAM3 ratio | GCST90314276 | 23.20 |
| 231 | DTI autoptx L1 cst l tract | GCST90385147 | 23.15 |
| 232 | Basal cell carcinoma (MTAG) | GCST90137411 | 23.04 |
| 233 | DTI autoptx MD cgc l tract | GCST90385224 | 23.04 |
| 234 | DTI autoptx MD str r tract | GCST90385244 | 22.95 |
| 235 | Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditions | UKBB00000513 | 22.93 |
| 236 | SMPD3 levels | GCST90470685 | 22.88 |
| 237 | DTI TBSS MD Posterior limb of internal capsule L | GCST90384591 | 22.83 |
| 238 | RILP levels | GCST90470471 | 22.78 |
| 239 | Prescriptions - antispasmodic | UKBB00000666 | 22.76 |
| 240 | SKAP1 levels | GCST90470645 | 22.67 |
| 241 | Prescriptions - levothyroxine | thyroid hormone | UKBB00000687 | 22.67 |
| 242 | Prescriptions - thyroid hormone | hormone | UKBB00000705 | 22.67 |
| 243 | Rheumatoid arthritis (PheCode 714.1) | GCST90476230 | 22.58 |
| 244 | Takes medication for Thyroid problems? | GCST90475277 | 22.55 |
| 245 | LAIR2 levels | GCST90469729 | 22.51 |
| 246 | 3-methyl-2-oxobutyrate levels | GCST90199677 | 22.49 |
| 247 | CRTAM/TNFRSF9 ratio | GCST90314280 | 22.36 |
| 248 | Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35) | GCST90309369 | 22.32 |
| 249 | DTI TBSS L3 Genu of corpus callosum | GCST90384526 | 22.26 |
| 250 | Wheeze or whistling in the chest in last year (UKB data field 2316) | GCST90043614 | 22.24 |
| 251 | Non-cancer illness code, self-reported - hiatus hernia | Medical conditions | UKBB00000515 | 22.19 |
| 252 | Thyroid problems | GCST90475276 | 22.03 |
| 253 | Inflammatory bowel disease, strict (require KELA) | FING00000675 | 22.00 |
| 254 | GLO1 levels | GCST90469358 | 21.95 |
| 255 | DTI TBSS MD Genu of corpus callosum | GCST90384574 | 21.95 |
| 256 | Noninfective enteritis and colitis | FING00000881 | 21.94 |
| 257 | CRTAM/KLRD1 ratio | GCST90314277 | 21.93 |
| 258 | Type 1 diabetes, definitions combined | FING00001380 | 21.78 |
| 259 | CD6 levels | GCST90468644 | 21.75 |
| 260 | Fluid intelligence score decline (difference score) | GCST90565862 | 21.62 |
| 261 | Other diseases of upper respiratory tract | FING00001012 | 21.62 |
| 262 | Primary biliary cholangitis (PBC) | FING00001211 | 21.51 |
| 263 | IFI30 levels | GCST90469509 | 21.39 |
| 264 | Acute upper respiratory infections | FING00000034 | 21.29 |
| 265 | FASLG levels | GCST90469191 | 21.22 |
| 266 | APRT/CD63 ratio | GCST90313334 | 21.20 |
| 267 | TNFSF12 levels | GCST90274846 | 21.12 |
| 268 | LHPP levels | GCST90469768 | 20.96 |
| 269 | Allergic disease (asthma, hay fever or eczema) | GCST005038 | 20.89 |
| 270 | CLEC1B/DAB2 ratio | GCST90314086 | 20.89 |
| 271 | Treatment/medication code - ibuprofen | Medications | UKBB00000847 | 20.79 |
| 272 | T1 FreeSurfer aseg MaskVol-to-eTIV | GCST90384192 | 20.77 |
| 273 | Wheeze or whistling in the chest in last year | Breathing | UKBB00000912 | 20.72 |
| 274 | Nonspecific chest pain | circulatory system | UKBB00000527 | 20.71 |
| 275 | BMP7 levels | GCST90088157 | 20.69 |
| 276 | Medication use (drugs affecting bone structure and mineralization) | GCST90018773 | 20.68 |
| 277 | PCBD1 levels | GCST90470166 | 20.62 |
| 278 | SELPLG levels | GCST90470568 | 20.58 |
| 279 | Volume of right basal nucleus | GCST90475015 | 20.49 |
| 280 | Ceramide (d18:2/22:0) levels | GCST90024682 | 20.45 |
| 281 | Hypothyroidism | GCST90319320 | 20.25 |
| 282 | Diseases of white blood cells (PheCode 288) | GCST90475812 | 20.23 |
| 283 | Malignant neoplasm of lip, excluding all cancers (controls excluding all cancers) | FING00000764 | 20.18 |
| 284 | CWC15 levels | GCST90468920 | 20.10 |
| 285 | COPD/asthma/ILD related infections | FING00000353 | 20.08 |
| 286 | LYN/SIRT2 ratio | GCST90315349 | 20.05 |
| 287 | Erythematosquamous dermatosis (PheCode 690) | GCST90476170 | 19.98 |
| 288 | Multiple myeloma or monoclonal gammopathy of undetermined significance | GCST90624746 | 19.94 |
| 289 | Seborrheic dermatitis (PheCode 690.1) | GCST90476171 | 19.86 |
| 290 | CD79B/TNFRSF4 ratio | GCST90313903 | 19.82 |
| 291 | Asthma (more control exclusions) | FING00000113 | 19.82 |
| 292 | TNFRSF19 levels | GCST90088947 | 19.80 |
| 293 | DNA methylation-estimated granulocyte proportions | GCST90014287 | 19.79 |
| 294 | CXCL16/NOTCH1 ratio | GCST90314339 | 19.78 |
| 295 | Sporadic miscarriage | GCST011888 | 19.68 |
| 296 | CD300A levels | GCST90468619 | 19.56 |
| 297 | IL5RA/TNFRSF13B ratio | GCST90315164 | 19.53 |
| 298 | Asthma and allergy | FING00000115 | 19.51 |
| 299 | WARS levels | GCST90471066 | 19.45 |
| 300 | T1 FreeSurfer BA lh V2 exvivo thickness | GCST90385529 | 19.43 |
| 301 | Rosacea (PheCode 695.3) | GCST90476178 | 19.43 |
| 302 | Allergic asthma (mode) | FING00000066 | 19.41 |
| 303 | GZMA levels | GCST90469423 | 19.39 |
| 304 | PDCD1 levels | GCST90470181 | 19.25 |
| 305 | Conjunctivitis | FING00000346 | 19.23 |
| 306 | Melanomas of skin (PheCode 172.11) | GCST90475578 | 19.21 |
| 307 | aseg lh volume Hippocampus | GCST90002624 | 19.16 |
| 308 | CLC levels | GCST90468762 | 19.16 |
| 309 | Neurofibromatosis, type 2 | FING00000867 | 19.08 |
| 310 | Graves' disease (PheCode 242.1) | GCST90475644 | 19.06 |
| 311 | Nasal polyps | respiratory | UKBB00000494 | 18.94 |
| 312 | APBB1IP/POLR2F ratio | GCST90313300 | 18.92 |
| 313 | IL5RA levels | GCST90469600 | 18.88 |
| 314 | Hayfever | GCST90468131 | 18.81 |
| 315 | DTYMK levels | GCST90469049 | 18.78 |
| 316 | Other specified disorders of external ear | FING00001104 | 18.76 |
| 317 | GOPC/IRAK4 ratio | GCST90314954 | 18.76 |
| 318 | Skin color (cheek, ITA value) | GCST90502780 | 18.73 |
| 319 | Ulcerative colitis | GCST90018713 | 18.70 |
| 320 | PIKFYVE levels | GCST90470235 | 18.67 |
| 321 | Inflammatory bowel disease | GCST90432182 | 18.66 |
| 322 | Other/unspecified rheumatoid arthritis | FING00001126 | 18.65 |
| 323 | IL15/KLRD1 ratio | GCST90315149 | 18.48 |
| 324 | PAXX levels | GCST90470161 | 18.47 |
| 325 | Colitis, primary sclerosing, strict definition | FING00000313 | 18.45 |
| 326 | Lymphocyte percentage of white cells | GCST004632 | 18.45 |
| 327 | LTA4H levels | GCST90469812 | 18.35 |
| 328 | ICD10 O60: Preterm labor and delivery | GCST90454242 | 18.27 |
| 329 | Eosinophil count | GCST90002299 | 18.26 |
| 330 | Other and unspecified tonsillitis | FING00000954 | 18.20 |
| 331 | CD101 levels | GCST90468596 | 18.20 |
| 332 | Volume of right central nucleus | GCST90474916 | 18.17 |
| 333 | HSPA1A levels | GCST90469487 | 18.04 |
| 334 | Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive) | GCST90132227 | 18.03 |
| 335 | Coeliac disease | FING00000312 | 18.02 |
| 336 | C5 levels | GCST90468500 | 17.99 |
| 337 | Regional enteritis (PheCode 555.1) | GCST90476066 | 17.95 |
| 338 | TP53I3 levels | GCST90470937 | 17.94 |
| 339 | Blood cell traits latent factor 17 (white cell) | GCST90559259 | 17.93 |
| 340 | Rheumatoid arthritis | GCST90018690 | 17.90 |
| 341 | Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80) | GCST90668524 | 17.88 |
| 342 | PTPRC levels | GCST90470380 | 17.86 |
| 343 | Disorders of sclera, cornea, iris and ciliary body | FING00000458 | 17.84 |
| 344 | ICD10 N87: Dysplasia of cervix uteri | GCST90454218 | 17.80 |
| 345 | Inflammatory bowel disease and other gasteroenteritis and colitis (PheCode 555) | GCST90476065 | 17.78 |
| 346 | Other (seronegative) rheumatoid arthritis, wide | FING00000917 | 17.75 |
| 347 | aparc-a2009s rh thickness G-temporal-middle | GCST90003714 | 17.73 |
| 348 | CD27/NBL1 ratio | GCST90313774 | 17.73 |
| 349 | Other acute lower respiratory infections | FING00000921 | 17.72 |
| 350 | NAP1L4 levels | GCST90469998 | 17.63 |
| 351 | Ever Smoker | FING00000522 | 17.61 |
| 352 | Primary biliary cholangitis | GCST90061440 | 17.55 |
| 353 | Incidence of bisecting GlcNAc in all fucosylated disialylated structures (GP57) | GCST90668735 | 17.47 |
| 354 | DTI TBSS L3 Superior corona radiata L | GCST90384549 | 17.42 |
| 355 | LCN2/PGLYRP1 ratio | GCST90315306 | 17.37 |
| 356 | SIT1 levels | GCST90470644 | 17.32 |
| 357 | KIR2DL2 levels | GCST90469684 | 17.29 |
| 358 | Mean corpuscular hemoglobin concentration | GCST90018745 | 17.21 |
| 359 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502396 | 17.19 |
| 360 | Thyrotoxicosis | FING00001360 | 17.04 |
| 361 | Methods of admission to hospital (recoded) - Elective admission: Planned | Summary Administration | UKBB00000462 | 17.03 |
| 362 | BLNK levels | GCST90468448 | 17.02 |
| 363 | Alcohol-induced chronic pancreatitis | FING00000055 | 17.02 |
| 364 | THBS2 levels | GCST90470854 | 16.95 |
| 365 | Nasal polyp | Other diseases of upper respiratory tract | UKBB00000493 | 16.95 |
| 366 | Handedness (chirality/laterality) - Left-handed | Early life factors | UKBB00000302 | 16.93 |
| 367 | CD244 levels | GCST90468611 | 16.89 |
| 368 | SH2D1A levels | GCST90470617 | 16.89 |
| 369 | SRP14 levels | GCST90470742 | 16.88 |
| 370 | Multiple myeloma | GCST90624747 | 16.88 |
| 371 | Benign leiomyoma with endometriosis (controls excluding all cancers) | FING00000145 | 16.86 |
| 372 | AHNAK levels | GCST90468261 | 16.84 |
| 373 | Atopic/contact dermatitis due to other or unspecified (PheCode 939) | GCST90476289 | 16.83 |
| 374 | Thyrotoxicosis with diffuse goitre | FING00001361 | 16.77 |
| 375 | MAPRE3 levels | GCST90469859 | 16.73 |
| 376 | Mean reticulocyte volume | GCST90025975 | 16.71 |
| 377 | X-21285 levels | GCST90200576 | 16.66 |
| 378 | Crohn disease (strict definition, require KELA, min 2 HDR) | FING00000366 | 16.66 |
| 379 | Omega-3 fatty acids to total fatty acids percentage | GCST90502460 | 16.65 |
| 380 | Internal derangement of knee (PheCode 835) | GCST90476282 | 16.63 |
| 381 | Eosinophil count | GCST90018733 | 16.63 |
| 382 | CRTAM/PDCD1 ratio | GCST90314279 | 16.61 |
| 383 | PM: initial answer - Orange circle| Prospective memory | UKBB00000652 | 16.61 |
| 384 | Time spent watching television (TV) | Physical activity | UKBB00000821 | 16.58 |
| 385 | Lymphoid neoplasms (P-cell phenocluster) | GCST90624737 | 16.58 |
| 386 | T1 FreeSurfer DK rh supramarginal volume | GCST90385787 | 16.50 |
| 387 | Hypothyroidism, drug reimbursement | FING00000655 | 16.43 |
| 388 | Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80) | GCST90668758 | 16.40 |
| 389 | Lung cancer | GCST90018655 | 16.39 |
| 390 | CCL17/CD69 ratio | GCST90313684 | 16.37 |
| 391 | OSMR levels | GCST90470132 | 16.33 |
| 392 | STIP1 levels | GCST90470764 | 16.33 |
| 393 | LCN2/S100A12 ratio | GCST90315309 | 16.26 |
| 394 | Plasma taurocholenate sulfate* levels in chronic kidney disease | GCST90266040 | 16.24 |
| 395 | Percentage of fucosylation of monogalactosylated structures in total neutral plasma glycans (GP74) | GCST90668518 | 16.22 |
| 396 | Left-hemisphere control network to amygdala white-matter structural connectivity | GCST90302757 | 16.21 |
| 397 | DCTN1/TRIAP1 ratio | GCST90314434 | 16.12 |
| 398 | Preterm labour and delivery | FING00001209 | 16.11 |
| 399 | Primary biliary cholangitis | GCST003129 | 16.08 |
| 400 | Basal cell carcinoma (PheCode 172.21) | GCST90475582 | 16.06 |
| 401 | CLIC5 levels | GCST90421740 | 16.04 |
| 402 | Overweight, obesity and other hyperalimentation | endocrine/metabolic | UKBB00000622 | 16.02 |
| 403 | CD48/SLAMF7 ratio | GCST90313842 | 16.00 |
| 404 | GP6/HPCAL1 ratio | GCST90314963 | 15.99 |
| 405 | Operation code - tonsillectomy +/- adenoids | Operations | UKBB00000567 | 15.97 |
| 406 | Methods of admission to hospital (recoded) - Elective admission: Booked | Summary Administration | UKBB00000461 | 15.97 |
| 407 | aparc-Desikan rh volume insula | GCST90002834 | 15.86 |
| 408 | Eosinophil count | GCST90025987 | 15.85 |
| 409 | ICD10 N84: Polyp of female genital tract | GCST90454216 | 15.83 |
| 410 | HLA-A levels | GCST90469457 | 15.81 |
| 411 | mean corpuscular volume (MCV, minimum, inv-norm transformed) | GCST90475474 | 15.79 |
| 412 | Autoimmune hyperthyroidism | FING00000134 | 15.75 |
| 413 | FOXO1/USP8 ratio | GCST90314879 | 15.71 |
| 414 | PFKM levels | GCST90618802 | 15.71 |
| 415 | Ceramide (d18:2/22:0) levels | GCST90024054 | 15.66 |
| 416 | IL16 levels | GCST90469557 | 15.65 |
| 417 | Non-cancer illness code, self-reported - eczema/dermatitis | Medical conditions | UKBB00000509 | 15.64 |
| 418 | mean corpuscular volume (MCV, mean, inv-norm transformed) | GCST90475470 | 15.64 |
| 419 | Educational attainment | GCST002598 | 15.62 |
| 420 | LSP1 levels | GCST90469811 | 15.60 |
| 421 | Coeliac disease | GCST90468120 | 15.58 |
| 422 | AHSP/HMBS ratio | GCST90313217 | 15.53 |
| 423 | CRTAP levels | GCST90468872 | 15.51 |
| 424 | Mean corpuscular hemoglobin concentration | GCST90002329 | 15.50 |
| 425 | Sarcoidosis | FING00001275 | 15.47 |
| 426 | Volume of right paralaminar nucleus | GCST90475051 | 15.45 |
| 427 | Other non-epithelial cancer of skin | neoplasms | UKBB00000615 | 15.45 |
| 428 | Mean reticulocyte volume | Blood count | UKBB00000451 | 15.44 |
| 429 | ST13 levels | GCST90470751 | 15.42 |
| 430 | CCL19 levels | GCST90468571 | 15.40 |
| 431 | Ulcerative colitis | GCST004133 | 15.34 |
| 432 | JCHAIN levels | GCST90469661 | 15.31 |
| 433 | IGBP1 levels | GCST90469521 | 15.28 |
| 434 | PBLD levels | GCST90470163 | 15.27 |
| 435 | KLRF1 levels | GCST90469712 | 15.25 |
| 436 | GRAP2/SRC ratio | GCST90314989 | 15.25 |
| 437 | Chalazion | FING00000267 | 15.25 |
| 438 | Hair colour (natural, before greying) - Black | Sun exposure | UKBB00000295 | 15.19 |
| 439 | CD5/IL16 ratio | GCST90313861 | 15.19 |
| 440 | S100A12 levels | GCST90470513 | 15.19 |
| 441 | Sicca syndrome [Sjögren] | FING00001304 | 15.16 |
| 442 | PAG1 levels | GCST90470147 | 15.15 |
| 443 | mean corpuscular volume (MCV, maximum, inv-norm transformed) | GCST90475466 | 15.15 |
| 444 | Graves' disease | GCST90018627 | 15.11 |
| 445 | Basophil count | GCST90002293 | 14.99 |
| 446 | red blood cell count (RBC, mean, inv-norm transformed) | GCST90476347 | 14.96 |
| 447 | CD40LG/TRAF2 ratio | GCST90313828 | 14.94 |
| 448 | LBR/POLR2F ratio | GCST90315297 | 14.93 |
| 449 | ZNF830 levels | GCST90471102 | 14.91 |
| 450 | DNAJB2 levels | GCST90469013 | 14.91 |
| 451 | FCRL5/LY96 ratio | GCST90314803 | 14.91 |
| 452 | CD300E/EFNA4 ratio | GCST90313797 | 14.90 |
| 453 | Volume of left central nucleus | GCST90474883 | 14.78 |
| 454 | IDP dMRI TBSS ICVF Medial lemniscus R | GCST90004335 | 14.74 |
| 455 | EDAR/F2R ratio | GCST90314577 | 14.70 |
| 456 | Mean sphered cell volume (UKB data field 30270) | GCST90468089 | 14.65 |
| 457 | F-caffeinated/sweet liking (derived food-liking factor) | GCST90094720 | 14.60 |
| 458 | Lumbar disc prolapse | FING00000735 | 14.60 |
| 459 | Other malignant neoplasms of skin | Melanoma and other malignant neoplasms of skin | UKBB00000613 | 14.57 |
| 460 | Psoriatic arthropathies | FING00001225 | 14.57 |
| 461 | SH2B3/TBL1X ratio | GCST90315841 | 14.56 |
| 462 | Lung adenocarcinoma | GCST004744 | 14.50 |
| 463 | Principal component-derived dietary pattern 21 | GCST90133026 | 14.49 |
| 464 | Diseases of vocal cords and larynx+other diseases of upper respiratory tract, no elsewhere classified | FING00000432 | 14.48 |
| 465 | Melanoma | GCST90011809 | 14.43 |
| 466 | FUT8/RSPO1 ratio | GCST90314891 | 14.41 |
| 467 | T1 FreeSurfer DKT rh supramarginal volume | GCST90384377 | 14.41 |
| 468 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475450 | 14.37 |
| 469 | HBEGF/PLXNA4 ratio | GCST90315036 | 14.37 |
| 470 | CXCL11/DKK1 ratio | GCST90314334 | 14.35 |
| 471 | Volume of left anterior amygdaloid area | GCST90474937 | 14.33 |
| 472 | Nasal polyps (PheCode 471) | GCST90476019 | 14.33 |
| 473 | Pilonidal cyst | FING00001167 | 14.32 |
| 474 | CD27/TGFBR2 ratio | GCST90313776 | 14.31 |
| 475 | mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed) | GCST90475442 | 14.26 |
| 476 | Asthma | GCST90475259 | 14.25 |
| 477 | DTI TBSS MD Superior longitudinal fasciculus L | GCST90384613 | 14.24 |
| 478 | Treatment speciality of consultant (recoded) - Trauma & orthopaedics | Summary Administration | UKBB00000837 | 14.18 |
| 479 | Bread type: Wholemeal/wholegrain vs white and brown (UKB data field 1448) | GCST90132968 | 14.18 |
| 480 | Acute pancreatitis | FING00000027 | 14.18 |
| 481 | TOR1AIP1 levels | GCST90470935 | 14.17 |
| 482 | IL10 levels | GCST90469546 | 14.17 |
| 483 | HippSubfield lh volume CA4-body | GCST90002683 | 14.17 |
| 484 | ROR1/THBD ratio | GCST90315786 | 14.16 |
| 485 | PARK7 levels | GCST90470159 | 14.15 |
| 486 | Skin cancer | GCST90475575 | 14.11 |
| 487 | Asthma-related pneumonia | FING00000119 | 14.11 |
| 488 | CD27/TNFRSF9 ratio | GCST90313778 | 14.11 |
| 489 | CD27/DLL1 ratio | GCST90313771 | 14.09 |
| 490 | MICB or MICA levels | GCST90469905 | 14.09 |
| 491 | Urine N-acetylglutamate levels in chronic kidney disease | GCST90265569 | 14.08 |
| 492 | Myo-inositol levels | GCST90243527 | 14.07 |
| 493 | UGDH levels | GCST90471006 | 14.07 |
| 494 | ENO3 levels | GCST90469111 | 14.06 |
| 495 | aparc-Desikan lh area fusiform | GCST90003079 | 14.06 |
| 496 | LBR levels | GCST90469744 | 14.04 |
| 497 | IBD (strict) with PSC | FING00000657 | 14.01 |
| 498 | Hair colour (natural, before greying): Dark brown (UKB data field 1747_4) | GCST90041839 | 14.00 |
| 499 | DTI autoptx L1 cst r tract | GCST90385148 | 14.00 |
| 500 | Ever taken cannabis | Cannabis use | UKBB00000224 | 13.95 |
| 501 | MAP2K1 levels | GCST90469851 | 13.91 |
| 502 | T1 FreeSurfer DK lh lingual thickness | GCST90385634 | 13.90 |
| 503 | Basophil count | GCST90018726 | 13.90 |
| 504 | CLEC4D/CLEC6A ratio | GCST90314109 | 13.87 |
| 505 | Obesity | endocrine/metabolic | UKBB00000544 | 13.86 |
| 506 | Percentage of monosialylation of core-fucosylated monogalactosylated structures without bisecting GlcNAc (GP41) | GCST90668485 | 13.84 |
| 507 | DXO levels | GCST90469055 | 13.82 |
| 508 | Viral haemorrhagic fevers, not elsewhere classified/unspecified | FING00001433 | 13.81 |
| 509 | CD27/NECTIN4 ratio | GCST90313775 | 13.80 |
| 510 | T1 FreeSurfer aseg Right-Pallidum | GCST90384164 | 13.80 |
| 511 | MICB_MICA/TEK ratio | GCST90315446 | 13.77 |
| 512 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475446 | 13.77 |
| 513 | Rheumatoid arthritis | GCST000679 | 13.76 |
| 514 | Melanomas of skin, dx or hx (PheCode 172.1) | GCST90475577 | 13.72 |
| 515 | IDP dMRI TBSS OD Posterior limb of internal capsule L | GCST90004421 | 13.72 |
| 516 | Hair colour (natural, before greying) - Dark brown | Sun exposure | UKBB00000297 | 13.70 |
| 517 | BCL2 levels | GCST90468433 | 13.65 |
| 518 | Obesity | Obesity and other hyperalimentation | UKBB00000545 | 13.63 |
| 519 | Malignant neoplasm of skin, excluding all cancers (controls excluding all cancers) | FING00000772 | 13.61 |
| 520 | FCRL5/ICAM3 ratio | GCST90314802 | 13.61 |
| 521 | Belief that own life is meaningful | Happiness and subjective well-being | UKBB00000090 | 13.59 |
| 522 | STX6 levels | GCST90470774 | 13.58 |
| 523 | UBXN1 levels | GCST90471004 | 13.56 |
| 524 | MAVS/MED18 ratio | GCST90315389 | 13.53 |
| 525 | Skin cancer | GCST90475189 | 13.50 |
| 526 | Mean sphered cell volume | Blood count | UKBB00000452 | 13.49 |
| 527 | TNFSF14 levels | GCST90470922 | 13.49 |
| 528 | CSNK1D levels | GCST90468888 | 13.47 |
| 529 | Congenital malformations of ovaries, fallopian tubes and broad ligaments | FING00000337 | 13.46 |
| 530 | DTI TBSS MD External capsule L | GCST90384605 | 13.46 |
| 531 | KLF4 levels | GCST90469694 | 13.44 |
| 532 | TIGIT levels | GCST90470865 | 13.44 |
| 533 | Omega-3 fatty acids to total fatty acids percentage | GCST90502448 | 13.42 |
| 534 | aparc-a2009s rh thickness G-oc-temp-med-Lingual | GCST90003698 | 13.40 |
| 535 | CLPS/PLA2G1B ratio | GCST90314140 | 13.38 |
| 536 | Tea difference liking | GCST90094855 | 13.35 |
| 537 | White blood cell count | GCST90025985 | 13.35 |
| 538 | Other non-epithelial cancer of skin (PheCode 172.2) | GCST90475580 | 13.34 |
| 539 | Number of attempts | Prospective memory | UKBB00000531 | 13.31 |
| 540 | Hair colour (natural, before greying): Red (UKB data field 1747_2) | GCST90041837 | 13.25 |
| 541 | Pollinosis | GCST90018683 | 13.24 |
| 542 | PDCD5 levels | GCST90470182 | 13.21 |
| 543 | Ulcerative colitis (strict definition, require KELA, min 2 HDR) | FING00001388 | 13.20 |
| 544 | Treatment/medication code - ventolin 100micrograms inhaler | Medications | UKBB00000860 | 13.17 |
| 545 | Monoclonal gammopathy of undetermined significance | GCST90624745 | 13.17 |
| 546 | Paraproteinemia (PheCode 270.32) | GCST90475710 | 13.11 |
| 547 | LAT/PLXNA4 ratio | GCST90315286 | 13.09 |
| 548 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 101) | GCST90320920 | 13.09 |
| 549 | Principal component-derived dietary pattern 12 | GCST90133017 | 13.06 |
| 550 | HippSubfield lh volume GC-ML-DG-head | GCST90002679 | 13.03 |
| 551 | Types of physical activity in last 4 weeks - None of the above | Physical activity | UKBB00000872 | 13.01 |
| 552 | neutrophil (fraction, minimum, inv-norm transformed) | GCST90475541 | 13.00 |
| 553 | Interpolated Year when non-cancer illness first diagnosed | Medical conditions | UKBB00000371 | 12.99 |
| 554 | UCMA levels | GCST90243285 | 12.90 |
| 555 | CDKN2D/FOXO1 ratio | GCST90313985 | 12.87 |
| 556 | FOXO3 levels | GCST90469266 | 12.82 |
| 557 | Pre-existing hypertension complicating pregnancy, childbirth and the puerperium | FING00001203 | 12.82 |
| 558 | ADAM15 levels | GCST90468217 | 12.80 |
| 559 | T1 FreeSurfer a2009s lh S postcentral area | GCST90384734 | 12.79 |
| 560 | DGKA levels | GCST90468989 | 12.78 |
| 561 | Squamous cell carcinoma (PheCode 172.22) | GCST90475583 | 12.75 |
| 562 | DTI autoptx L3 str r tract | GCST90385217 | 12.75 |
| 563 | Pain in throat and chest | Symptoms and signs involving the circulatory and respiratory systems | UKBB00000625 | 12.71 |
| 564 | CEP85 levels | GCST90468716 | 12.66 |
| 565 | DNA methylation PhenoAge acceleration | GCST90014292 | 12.64 |
| 566 | CD27 levels | GCST90468615 | 12.64 |
| 567 | neutrophil (fraction, mean, inv-norm transformed) | GCST90475538 | 12.63 |
| 568 | Celiac disease (PheCode 557.1) | GCST90044158 | 12.58 |
| 569 | Non-albumin protein levels | UKBB00000503 | 12.54 |
| 570 | Crohn's disease NAS | FING00000367 | 12.53 |
| 571 | CXCL16 levels | GCST90240524 | 12.53 |
| 572 | DTI TBSS MD Anterior corona radiata L | GCST90384595 | 12.50 |
| 573 | KLRD1/LY9 ratio | GCST90315261 | 12.46 |
| 574 | Epstein-Barr virus ZEBRA antibody levels | GCST90006901 | 12.46 |
| 575 | PM: initial answer - Blue square | Prospective memory | UKBB00000651 | 12.46 |
| 576 | Plasma homoarginine levels in chronic kidney disease | GCST90265345 | 12.43 |
| 577 | Other dyspnea (PheCode 512.9) | GCST90476042 | 12.41 |
| 578 | Human herpes virus 7 U14 antibody levels | GCST90006909 | 12.41 |
| 579 | PDCD1/TNFRSF8 ratio | GCST90315610 | 12.41 |
| 580 | BAG6/BMP6 ratio | GCST90313450 | 12.40 |
| 581 | Hyperthyroidism | GCST90319319 | 12.40 |
| 582 | Bipolar disorder | GCST003724 | 12.39 |
| 583 | F2R/TNFRSF14 ratio | GCST90314739 | 12.37 |
| 584 | MVK/SERPINE1 ratio | GCST90315505 | 12.36 |
| 585 | PEAR1/PECAM1 ratio | GCST90315641 | 12.35 |
| 586 | Acute renal failure | FING00000030 | 12.28 |
| 587 | Mean corpuscular hemoglobin | GCST90002390 | 12.28 |
| 588 | Allergic conjunctivitis | FING00000067 | 12.26 |
| 589 | IDP T1 FAST ROIs R front operc cortex | GCST90002532 | 12.24 |
| 590 | Completion of the aide-memoire | GCST90012793 | 12.24 |
| 591 | CDKN2D/TACC3 ratio | GCST90313992 | 12.22 |
| 592 | Bread type - Wholemeal or wholegrain | Diet | UKBB00000107 | 12.21 |
| 593 | DTI autoptx L3 slf r tract | GCST90385215 | 12.21 |
| 594 | FCRL5 levels | GCST90469208 | 12.18 |
| 595 | TNF levels | GCST90470924 | 12.18 |
| 596 | Psoriasis (vulgaris), strict definition | FING00001223 | 12.16 |
| 597 | Basophil count | GCST90025997 | 12.14 |
| 598 | Crohn's disease | GCST90446793 | 12.13 |
| 599 | NRSN1 levels | GCST90242062 | 12.09 |
| 600 | Neutrophill percentage (UKB data field 30200) | GCST90468093 | 12.08 |
| 601 | Neutrophil percentage of white cells | GCST90002399 | 12.06 |
| 602 | Pain in limb | FING00001138 | 12.05 |
| 603 | SPINK2 levels | GCST90470722 | 12.04 |
| 604 | Cervical cancer | GCST90011816 | 12.03 |
| 605 | 5-oxoproline levels | GCST90243437 | 12.01 |
| 606 | Biological Mother: High blood pressure | GCST90475490 | 12.00 |
| 607 | SEMA4D levels | GCST90470573 | 11.96 |
| 608 | PLXNA4/SUSD1 ratio | GCST90315689 | 11.93 |
| 609 | HSPB1 levels | GCST90179317 | 11.93 |
| 610 | GMPR2 levels | GCST90469367 | 11.93 |
| 611 | CD27/CD79B ratio | GCST90313770 | 11.92 |
| 612 | Hernia abdominopelvic cavity | GCST90086087 | 11.90 |
| 613 | Prospective memory result | Prospective memory | UKBB00000713 | 11.89 |
| 614 | ICD10 N97.8: Female infertility of other origin | GCST90454225 | 11.88 |
| 615 | Biological Sibling: Asthma | GCST90476372 | 11.86 |
| 616 | Lung cancer | GCST004748 | 11.85 |
| 617 | Ratio of bis-allylic bonds to double bonds in lipids | GCST90132744 | 11.85 |
| 618 | DTI TBSS L2 Genu of corpus callosum | GCST90384478 | 11.83 |
| 619 | Fluid intelligence score decline (log-difference score) | GCST90565852 | 11.82 |
| 620 | DEFA1_DEFA1B/PTGDS ratio | GCST90314455 | 11.82 |
| 621 | KLRK1 levels | GCST90469713 | 11.81 |
| 622 | ARHGAP25/RNF41 ratio | GCST90313345 | 11.76 |
| 623 | EDAR/ERBIN ratio | GCST90314575 | 11.75 |
| 624 | Mean reticulocyte volume (UKB data field 30260) | GCST90468088 | 11.74 |
| 625 | BCL2L15 levels | GCST90468431 | 11.74 |
| 626 | Neutrophill percentage | Blood count | UKBB00000498 | 11.72 |
| 627 | BTN3A2 levels | GCST90468481 | 11.72 |
| 628 | Bread type: Wholemeal or wholegrain (UKB data field 1448_3) | GCST90132966 | 11.71 |
| 629 | MSRA/PRDX5 ratio | GCST90315497 | 11.68 |
| 630 | AXIN1/MAVS ratio | GCST90313414 | 11.66 |
| 631 | Mean spheric corpuscular volume | GCST90002397 | 11.65 |
| 632 | Other intervertebral disc disorders | FING00001063 | 11.65 |
| 633 | Oxalate (ethanedioate) levels | GCST90199672 | 11.65 |
| 634 | TPSAB1 levels | GCST90470951 | 11.64 |
| 635 | GGACT levels | GCST90469333 | 11.63 |
| 636 | GP1BA/HBEGF ratio | GCST90314956 | 11.63 |
| 637 | BCR/FOXO1 ratio | GCST90313490 | 11.58 |
| 638 | Systemic connective tissue disorders | FING00001350 | 11.55 |
| 639 | Rheumatoid arthritis | musculoskeletal | UKBB00000757 | 11.55 |
| 640 | CD72 levels | GCST90468646 | 11.54 |
| 641 | DTI TBSS MD Superior corona radiata R | GCST90384596 | 11.54 |
| 642 | DTI TBSS L3 Sagittal stratum L | GCST90384555 | 11.53 |
| 643 | Back pain (PheCode 760) | GCST90476266 | 11.52 |
| 644 | HBEGF/WWP2 ratio | GCST90315038 | 11.50 |
| 645 | DTI autoptx L1 slf r tract | GCST90385161 | 11.50 |
| 646 | HippSubfield lh volume GC-ML-DG-body | GCST90002681 | 11.49 |
| 647 | Eosinophil count variance | GCST90565689 | 11.49 |
| 648 | XCL1 levels | GCST90471081 | 11.48 |
| 649 | Mean reticulocyte volume | GCST90002396 | 11.48 |
| 650 | Crohn's disease of small intestine | FING00000369 | 11.44 |
| 651 | Blood cell traits latent factor 12 (red cell) | GCST90559254 | 11.42 |
| 652 | Other dorsopathies, not elsewhere classified | FING00001041 | 11.42 |
| 653 | EDAR/TACC3 ratio | GCST90314589 | 11.42 |
| 654 | MAN2B2 levels | GCST90469844 | 11.42 |
| 655 | Mean corpuscular hemoglobin | GCST004630 | 11.42 |
| 656 | Seminoma of testis, excluding all cancers (controls excluding all cancers) | FING00001289 | 11.39 |
| 657 | Mean corpuscular volume | GCST90002392 | 11.39 |
| 658 | ALB/Globulin ratio | UKBB00000020 | 11.38 |
| 659 | Rheumatoid arthritis and other inflammatory polyarthropathies | musculoskeletal | UKBB00000758 | 11.36 |
| 660 | MAVS/TBL1X ratio | GCST90315399 | 11.35 |
| 661 | Type 1 diabetes | GCST90018705 | 11.35 |
| 662 | QDPR levels | GCST90470400 | 11.32 |
| 663 | HippSubfield lh volume Whole-hippocampus | GCST90002689 | 11.31 |
| 664 | IPCEF1/SPARC ratio | GCST90315186 | 11.31 |
| 665 | N2-acetyl,N6,N6-dimethyllysine levels | GCST90200697 | 11.31 |
| 666 | Endometrial cancer | GCST006464 | 11.30 |
| 667 | LAYN/PTPRN2 ratio | GCST90315290 | 11.28 |
| 668 | ENO2/RWDD1 ratio | GCST90314667 | 11.28 |
| 669 | CEACAM8/PGLYRP1 ratio | GCST90314003 | 11.28 |
| 670 | HippSubfield lh volume Hippocampal-tail | GCST90002668 | 11.21 |
| 671 | GPI levels | GCST90469391 | 11.18 |
| 672 | CCS levels | GCST90468594 | 11.16 |
| 673 | APRT/PSME1 ratio | GCST90313338 | 11.13 |
| 674 | Mean corpuscular volume (UKB data field 30040) | GCST90468086 | 11.13 |
| 675 | DTI TBSS MD Superior longitudinal fasciculus R | GCST90384612 | 11.13 |
| 676 | Mouth/teeth dental problems - None of the above | Mouth | UKBB00000489 | 11.12 |
| 677 | Actinic keratosis | FING00000013 | 11.11 |
| 678 | Eosinophil percentage of white cells variance | GCST90565690 | 11.10 |
| 679 | KYNU/SCLY ratio | GCST90315265 | 11.07 |
| 680 | Cervical disc disorders | FING00000265 | 11.06 |
| 681 | FUT8/TNFSF14 ratio | GCST90314895 | 11.04 |
| 682 | Mean corpuscular haemoglobin (UKB data field 30050) | GCST90468084 | 11.04 |
| 683 | Ulcerative colitis (PheCode 555.2) | GCST90044155 | 11.03 |
| 684 | DNAJC9 levels | GCST90469018 | 11.03 |
| 685 | CDH17/PTPRM ratio | GCST90313943 | 11.02 |
| 686 | ITGB2 levels | GCST90469644 | 10.99 |
| 687 | CA3/HMBS ratio | GCST90313584 | 10.97 |
| 688 | Cancer of bronchus; lung (PheCode 165.1) | GCST90475573 | 10.96 |
| 689 | Overweight, obesity and other hyperalimentation (PheCode 278) | GCST90475759 | 10.94 |
| 690 | Attendance/disability/mobility allowance - None of the above | Other sociodemographic factors | UKBB00000059 | 10.94 |
| 691 | TRAF2/WWP2 ratio | GCST90315943 | 10.94 |
| 692 | YOD1 levels | GCST90471090 | 10.94 |
| 693 | CD20 on IgD- CD27- B cell | GCST90001754 | 10.93 |
| 694 | Age hay fever, rhinitis or eczema diagnosed | Medical conditions | UKBB00000015 | 10.93 |
| 695 | Destinations on discharge from hospital (recoded) - Usual Place of residence | Summary Administration | UKBB00000167 | 10.91 |
| 696 | Actinic keratosis (PheCode 702.1) | GCST90476204 | 10.90 |
| 697 | PRL levels | GCST90470332 | 10.90 |
| 698 | GBP4 levels | GCST90469313 | 10.89 |
| 699 | DNAJA2/PLXNA4 ratio | GCST90314504 | 10.88 |
| 700 | SUMF1 levels | GCST90470783 | 10.86 |
| 701 | Mean corpuscular haemoglobin | Blood count | UKBB00000447 | 10.84 |
| 702 | Neoplasm of uncertain behavior (PheCode 199) | GCST90475606 | 10.84 |
| 703 | RIDA levels | GCST90470469 | 10.81 |
| 704 | CD163/ICAM1 ratio | GCST90313735 | 10.80 |
| 705 | APRT/MIF ratio | GCST90313336 | 10.77 |
| 706 | Principal component-derived dietary pattern 9 | GCST90133014 | 10.76 |
| 707 | Sources of admission to hospital (recoded) - Usual Place of residence | Summary Administration | UKBB00000786 | 10.75 |
| 708 | Solitary pulmonary nodule (PheCode 514.2) | GCST90476044 | 10.74 |
| 709 | Acute sinusitis | FING00000031 | 10.74 |
| 710 | DTI TBSS MD Anterior limb of internal capsule L | GCST90384589 | 10.72 |
| 711 | Neoplasm of uncertain behavior of skin (PheCode 173) | GCST90475585 | 10.71 |
| 712 | Peripheral enthesopathies and allied syndromes | musculoskeletal | UKBB00000640 | 10.69 |
| 713 | Phenylacetate levels | GCST90199630 | 10.68 |
| 714 | Crohn's disease | GCST004132 | 10.66 |
| 715 | CRACR2A/IRAG2 ratio | GCST90314227 | 10.64 |
| 716 | CRYBB1 levels | GCST90468874 | 10.64 |
| 717 | Cancer within the respiratory system (PheCode 165) | GCST90475571 | 10.61 |
| 718 | Early-onset myasthenia gravis | GCST90093465 | 10.61 |
| 719 | CD58/MEGF10 ratio | GCST90313853 | 10.60 |
| 720 | PTPRS levels | GCST90470387 | 10.60 |
| 721 | Acute bronchitis | FING00000021 | 10.57 |
| 722 | Spondylopathies (FG) | FING00001326 | 10.56 |
| 723 | neutrophil (fraction, maximum, inv-norm transformed) | GCST90475535 | 10.54 |
| 724 | Ulcerative colitis, NAS | FING00001390 | 10.53 |
| 725 | Symptoms involving digestive system (PheCode 561) | GCST90476069 | 10.49 |
| 726 | ITGB1BP2/TIA1 ratio | GCST90315222 | 10.47 |
| 727 | CC2D1A/STAMBP ratio | GCST90313664 | 10.47 |
| 728 | SOD1 levels | GCST90470704 | 10.46 |
| 729 | SH3GLB2 levels | GCST90470621 | 10.46 |
| 730 | HNRNPUL1 levels | GCST90469470 | 10.44 |
| 731 | Volume of right accessory basal nucleus | GCST90475009 | 10.44 |
| 732 | Telomere length (principal component 1) | GCST90435144 | 10.42 |
| 733 | DTI TBSS MD Cingulum cingulate gyrus L | GCST90384607 | 10.42 |
| 734 | CCL3 levels | GCST90468582 | 10.41 |
| 735 | VSTM2B levels | GCST90471056 | 10.37 |
| 736 | AK1 levels | GCST90468269 | 10.37 |
| 737 | IL7 levels | GCST90469606 | 10.34 |
| 738 | HippSubfield lh volume CA4-head | GCST90002682 | 10.34 |
| 739 | Parental longevity (combined parental age at death) | GCST006702 | 10.32 |
| 740 | PTRHD1 levels | GCST90470389 | 10.31 |
| 741 | VNN2 levels | GCST90471044 | 10.31 |
| 742 | CASP10 levels | GCST90468542 | 10.29 |
| 743 | CD84/F2R ratio | GCST90313912 | 10.29 |
| 744 | EDIL3 levels | GCST90469072 | 10.28 |
| 745 | FCRL2/LY9 ratio | GCST90314799 | 10.26 |
| 746 | IGF1R levels | GCST90469524 | 10.26 |
| 747 | Degenerative skin conditions and other dermatoses (PheCode 702) | GCST90476202 | 10.24 |
| 748 | Rheumatoid arthritis and other inflammatory (PheCode 714) | GCST90476228 | 10.23 |
| 749 | Dermatomycosis (PheCode 110.2) | GCST90475565 | 10.21 |
| 750 | SIAE levels | GCST90470629 | 10.20 |
| 751 | Lichen simplex chronicus and prurigo | FING00000725 | 10.20 |
| 752 | ITGB7 levels | GCST90469647 | 10.19 |
| 753 | Basal cell carcinoma, including avohilmo, excluding all cancers (controls excluding all cancers) | FING00000143 | 10.17 |
| 754 | Other systemic involvement of connective tissue (FG) | FING00001116 | 10.14 |
| 755 | Mean corpuscular volume | GCST004602 | 10.13 |
| 756 | VCAM1 levels | GCST90471031 | 10.13 |
| 757 | aparc-DKTatlas lh area fusiform | GCST90003239 | 10.13 |
| 758 | SNX15 levels | GCST90470699 | 10.13 |
| 759 | Tea with sugar liking | GCST90094857 | 10.11 |
| 760 | PRG3 levels | GCST90470323 | 10.11 |
| 761 | Current Smoker | FING00000371 | 10.07 |
| 762 | Ankylosing spondylitis | FING00000089 | 10.06 |
| 763 | BOC levels | GCST90468458 | 10.06 |
| 764 | IMPACT levels | GCST90469611 | 10.04 |
| 765 | TNF/TNFRSF1B ratio | GCST90315942 | 10.03 |
| 766 | CD6/EZR ratio | GCST90313890 | 10.01 |
| 767 | PEBP1 levels | GCST90470205 | 9.99 |
| 768 | Ingrowing nail (PheCode 703.1) | GCST90476208 | 9.97 |
| 769 | Gastric ulcer | GCST90018631 | 9.94 |
| 770 | CXCL5/PLXNA4 ratio | GCST90314351 | 9.90 |
| 771 | GRAP2/MAP4K5 ratio | GCST90314982 | 9.90 |
| 772 | Mean corpuscular volume | Blood count | UKBB00000449 | 9.90 |
| 773 | ATOX1/SNAP29 ratio | GCST90313374 | 9.88 |
| 774 | SNAP29/VEGFC ratio | GCST90315862 | 9.88 |
| 775 | APRT/EREG ratio | GCST90313335 | 9.84 |
| 776 | ELOA/POLR2F ratio | GCST90314643 | 9.84 |
| 777 | Dorsalgia | FING00000472 | 9.83 |
| 778 | NELL2/SEZ6L ratio | GCST90315536 | 9.82 |
| 779 | Peripheral or central vertigo (PheCode 386.2) | GCST90475907 | 9.81 |
| 780 | PXN levels | GCST90470396 | 9.81 |
| 781 | COX5B/GFER ratio | GCST90314200 | 9.80 |
| 782 | Ulcerative colitis | GCST90446795 | 9.80 |
| 783 | FCER2/TNFRSF9 ratio | GCST90314791 | 9.80 |
| 784 | T1 FreeSurfer a2009s lh S central thickness | GCST90384786 | 9.80 |
| 785 | Sjögren's syndrome | GCST90018700 | 9.79 |
| 786 | Phosphatidylcholine acyl-alkyl C36:4 levels | GCST90240072 | 9.77 |
| 787 | FHIT/GLOD4 ratio | GCST90314817 | 9.76 |
| 788 | SERPINE1/USP8 ratio | GCST90315835 | 9.74 |
| 789 | CD48 levels | GCST90468635 | 9.73 |
| 790 | FOXO1/NUB1 ratio | GCST90314874 | 9.73 |
| 791 | IL32 levels | GCST90469591 | 9.73 |
| 792 | FKBP4 levels | GCST90469243 | 9.73 |
| 793 | LBR/LGALS8 ratio | GCST90315294 | 9.72 |
| 794 | SLAMF8 levels | GCST90470652 | 9.71 |
| 795 | Takes medication for Skin condition (ex. Eczema, Psoriasis)? | GCST90475275 | 9.70 |
| 796 | Skin cancer | neoplasms | UKBB00000772 | 9.68 |
| 797 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T484 | ECGA000484 | 9.68 |
| 798 | Never eat wheat vs no wheat restrictions (UKB data field 6144) | GCST90132932 | 9.67 |
| 799 | DLG4 levels | GCST90469001 | 9.66 |
| 800 | CDA levels | GCST90468660 | 9.66 |
| 801 | Basal cell carcinoma, excluding all cancers (controls excluding all cancers) | FING00000142 | 9.66 |
| 802 | DBNL/EDAR ratio | GCST90314416 | 9.65 |
| 803 | T1 FreeSurfer BA lh BA2 exvivo volume | GCST90385534 | 9.65 |
| 804 | Urticaria | FING00001408 | 9.63 |
| 805 | CXCL16 levels | GCST90012059 | 9.63 |
| 806 | Pain in joint | FING00001137 | 9.63 |
| 807 | Carboplatin drug response (IC50) | GCST90011783 | 9.63 |
| 808 | Rhodanobacter abundance in stool | GCST90032536 | 9.62 |
| 809 | Trouble falling asleep when you first go to bed | GCST90476385 | 9.62 |
| 810 | Lower back pain or/and sciatica | FING00000731 | 9.60 |
| 811 | EDAR/LAT2 ratio | GCST90314582 | 9.60 |
| 812 | CCR2 on CD14+ CD16- monocyte | GCST90002004 | 9.60 |
| 813 | RCC1 levels | GCST90470443 | 9.60 |
| 814 | DTI autoptx L2 slf l tract | GCST90385187 | 9.59 |
| 815 | Strenuous sports or other exercises | GCST006100 | 9.56 |
| 816 | PDGFB/TNFSF13 ratio | GCST90315632 | 9.55 |
| 817 | ICAM3/SLAMF7 ratio | GCST90315123 | 9.53 |
| 818 | Poultry consumption | GCST90132996 | 9.53 |
| 819 | CA1/HMBS ratio | GCST90313573 | 9.52 |
| 820 | Eczema | GCST90468126 | 9.48 |
| 821 | TOP2B levels | GCST90470934 | 9.47 |
| 822 | Fibroblastic disorders | FING00000542 | 9.39 |
| 823 | DTI TBSS MD Body of corpus callosum | GCST90384575 | 9.39 |
| 824 | Severity of induration at injection site at the injection site after COVID-19 booster vaccination | GCST90454409 | 9.39 |
| 825 | BCR/DECR1 ratio | GCST90313489 | 9.38 |
| 826 | aseg lh volume Accumbens-area | GCST90002626 | 9.37 |
| 827 | APP/BIN2 ratio | GCST90313316 | 9.36 |
| 828 | Asthma | GCST90476024 | 9.36 |
| 829 | DTI TBSS L2 External capsule L | GCST90384509 | 9.36 |
| 830 | GRHPR levels | GCST90469400 | 9.35 |
| 831 | Late-onset myasthenia gravis | GCST90093466 | 9.35 |
| 832 | Percentage of fucosylation of monogalactosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP82) | GCST90668526 | 9.35 |
| 833 | EPHB6/TNFRSF9 ratio | GCST90314682 | 9.30 |
| 834 | IGLC2 levels | GCST90469536 | 9.28 |
| 835 | Neutrophil percentage of white cells | GCST004633 | 9.27 |
| 836 | APP/PPP1R12A ratio | GCST90313330 | 9.26 |
| 837 | Blood cell traits latent factor 20 (red cell) | GCST90559262 | 9.26 |
| 838 | Prurigo nodularis | FING00001220 | 9.25 |
| 839 | Tryptophan betaine levels | GCST90199819 | 9.24 |
| 840 | Other malignant neoplasms of skin (=non-melanoma skin cancer), excluding all cancers (controls excluding all cancers) | FING00001067 | 9.23 |
| 841 | PSAPL1 levels | GCST90242354 | 9.22 |
| 842 | Dissociative [conversion] disorders | FING00000468 | 9.21 |
| 843 | HMBS/PKLR ratio | GCST90315063 | 9.19 |
| 844 | Shortness of breath (PheCode 512.7) | GCST90476040 | 9.18 |
| 845 | F11R/PLXNA4 ratio | GCST90314724 | 9.17 |
| 846 | TRAF3 levels | GCST90470957 | 9.16 |
| 847 | Chromatiales abundance in stool | GCST90032318 | 9.15 |
| 848 | CCL13/CCL17 ratio | GCST90313674 | 9.14 |
| 849 | CAPG levels | GCST90468537 | 9.13 |
| 850 | DTI TBSS L3 Posterior thalamic radiation L | GCST90384553 | 9.13 |
| 851 | Fibrosis and cirrhosis of liver | FING00000543 | 9.12 |
| 852 | TNFRSF9 levels | GCST90470916 | 9.12 |
| 853 | Primary sclerosing cholangitis | GCST004030 | 9.10 |
| 854 | F2R/SNX9 ratio | GCST90314736 | 9.09 |
| 855 | FCRL1/TCL1A ratio | GCST90314795 | 9.09 |
| 856 | MZB1/TNFRSF13B ratio | GCST90315509 | 9.09 |
| 857 | Excessive scarring | GCST90483368 | 9.07 |
| 858 | Chronic hepatitis B infection | GCST90018584 | 9.07 |
| 859 | CA5A/GSTA1 ratio | GCST90313591 | 9.07 |
| 860 | DTI TBSS MD Posterior corona radiata L | GCST90384599 | 9.06 |
| 861 | IL22 levels | GCST90469582 | 9.05 |
| 862 | Basal cell carcinoma | GCST90013410 | 9.04 |
| 863 | X-16087 levels | GCST90200537 | 9.03 |
| 864 | Dorsopathies | FING00000473 | 9.02 |
| 865 | White blood cell count | GCST90002407 | 8.99 |
| 866 | DTI TBSS L2 Posterior thalamic radiation R | GCST90384504 | 8.99 |
| 867 | Dried fruit consumption | GCST90132980 | 8.97 |
| 868 | CASP8/PPP3R1 ratio | GCST90313654 | 8.97 |
| 869 | All dysplastic lesions of the cervix uteri | FING00000060 | 8.97 |
| 870 | HTRA2/SIAE ratio | GCST90315097 | 8.95 |
| 871 | Physical activity (Total log acceleration 8am-10am) | GCST90061413 | 8.95 |
| 872 | IL18BP/ROR1 ratio | GCST90315155 | 8.93 |
| 873 | LY96 levels | GCST90469823 | 8.92 |
| 874 | OCLN levels | GCST90470114 | 8.92 |
| 875 | N-acetylmethionine levels | GCST90200289 | 8.89 |
| 876 | Volume of right whole amygdala | GCST90475057 | 8.89 |
| 877 | CD69/EDAR ratio | GCST90313875 | 8.88 |
| 878 | Bifidobacterium catenulatum abundance in stool | GCST90032224 | 8.88 |
| 879 | Pollen allergy | FING00001176 | 8.85 |
| 880 | Hair colour (natural, before greying): Black (UKB data field 1747_5) | GCST90041840 | 8.83 |
| 881 | CD274 levels | GCST90274832 | 8.83 |
| 882 | BLMH/SERPINE1 ratio | GCST90313520 | 8.82 |
| 883 | Symptoms concerning nutrition, metabolism, and development (PheCode 1002) | GCST90475556 | 8.81 |
| 884 | Types of physical activity in last 4 weeks - Walking for pleasure (not as a means of transport) | Physical activity | UKBB00000875 | 8.81 |
| 885 | CD40LG/TNFSF14 ratio | GCST90313827 | 8.80 |
| 886 | DKK1/LGALS8 ratio | GCST90314472 | 8.80 |
| 887 | DTI TBSS L1 Cingulum cingulate gyrus L | GCST90384463 | 8.80 |
| 888 | Frequency of stair climbing in last 4 weeks | Physical activity | UKBB00000266 | 8.79 |
| 889 | SNAP23/SNAP29 ratio | GCST90315855 | 8.78 |
| 890 | Mean arterial pressure, manual reading | Cardiovascular measurement | UKBB00000441 | 8.76 |
| 891 | HEXIM1/TRIAP1 ratio | GCST90315054 | 8.75 |
| 892 | Crohn's disease of large intestine | FING00000368 | 8.74 |
| 893 | APRT/NSFL1C ratio | GCST90313337 | 8.74 |
| 894 | Crohns disease | GCST90468121 | 8.74 |
| 895 | CA5A/GRPEL1 ratio | GCST90313590 | 8.71 |
| 896 | CASP10/ING1 ratio | GCST90313625 | 8.71 |
| 897 | Volume of right central nucleus | GCST90475027 | 8.71 |
| 898 | Left-hemisphere visual network to accumbens white-matter structural connectivity | GCST90302668 | 8.70 |
| 899 | HippSubfield lh volume Whole-hippocampal-head | GCST90002688 | 8.70 |
| 900 | DTI TBSS L3 Superior longitudinal fasciculus R | GCST90384564 | 8.69 |
| 901 | NT5C levels | GCST90470092 | 8.69 |
| 902 | TNFRSF14/TNFSF14 ratio | GCST90315936 | 8.68 |
| 903 | Intended management of patient (recoded) - No overnight hospital stay | Summary Administration | UKBB00000366 | 8.68 |
| 904 | TYRO3 levels | GCST90470997 | 8.66 |
| 905 | White blood cell count | GCST90002374 | 8.66 |
| 906 | Diseases of the digestive system | FING00000429 | 8.66 |
| 907 | CD46/TIMP1 ratio | GCST90313837 | 8.64 |
| 908 | MIF levels | GCST90469906 | 8.63 |
| 909 | PPP1R12A/VEGFC ratio | GCST90315715 | 8.62 |
| 910 | Prescriptions - antipyretic | UKBB00000665 | 8.61 |
| 911 | Prescriptions - paracetamol | antipyretic | UKBB00000696 | 8.61 |
| 912 | Extrapyramidal and movement disorders | FING00000527 | 8.60 |
| 913 | Endometriosis | GCST90018619 | 8.59 |
| 914 | CXCL11 levels | GCST90468924 | 8.57 |
| 915 | Vanillactate levels | GCST90199978 | 8.56 |
| 916 | DTI autoptx L3 ifo l tract | GCST90385205 | 8.55 |
| 917 | DTI TBSS MD Anterior corona radiata R | GCST90384594 | 8.53 |
| 918 | CLEC1B levels | GCST90468768 | 8.51 |
| 919 | FKBP1B/PRDX5 ratio | GCST90314833 | 8.50 |
| 920 | Suppurative and unspecified otitis media | FING00001346 | 8.48 |
| 921 | Osteoarthrosis NOS (PheCode 740.9) | GCST90476256 | 8.45 |
| 922 | Never eat wheat vs no eggs, dairy, wheat or sugar restrictions (UKB data field 6144) | GCST90132931 | 8.44 |
| 923 | TNFRSF13B/TNFRSF9 ratio | GCST90315932 | 8.43 |
| 924 | ThalamNuclei rh volume MGN | GCST90002737 | 8.43 |
| 925 | Parkinson's disease | FING00001150 | 8.42 |
| 926 | DTI autoptx MD atr l tract | GCST90385222 | 8.41 |
| 927 | DAB2/FKBP1B ratio | GCST90314362 | 8.41 |
| 928 | SDC4/SEMA4D ratio | GCST90315818 | 8.40 |
| 929 | MAD1L1/POLR2F ratio | GCST90315354 | 8.40 |
| 930 | Edema (PheCode 782.3) | GCST90476272 | 8.40 |
| 931 | ENO2 levels | GCST90469110 | 8.39 |
| 932 | EIF4G1/FOXO1 ratio | GCST90314634 | 8.39 |
| 933 | TXNDC15 levels | GCST90470990 | 8.38 |
| 934 | Polyp of the female genital tract | FING00001190 | 8.38 |
| 935 | IDP dMRI TBSS FA Posterior limb of internal capsule R | GCST90003895 | 8.38 |
| 936 | NMT1 levels | GCST90470059 | 8.37 |
| 937 | PDCD1/TNFRSF4 ratio | GCST90315609 | 8.34 |
| 938 | AIDA levels | GCST90468265 | 8.31 |
| 939 | Asthma | GCST006862 | 8.31 |
| 940 | CCL5/LAMA4 ratio | GCST90313703 | 8.30 |
| 941 | CASP3/LYN ratio | GCST90313635 | 8.30 |
| 942 | CCL22/PDGFB ratio | GCST90313692 | 8.28 |
| 943 | RAP1A levels | GCST90470425 | 8.28 |
| 944 | Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS), excluding all cancers (controls excluding all cancers) | FING00000846 | 8.27 |
| 945 | Other symptoms of respiratory system (PheCode 512) | GCST90476039 | 8.27 |
| 946 | FOXO1/MAP4K5 ratio | GCST90314872 | 8.25 |
| 947 | FHIT levels | GCST90469238 | 8.25 |
| 948 | F2R levels | GCST90469168 | 8.24 |
| 949 | CDC37/SNAP29 ratio | GCST90313935 | 8.21 |
| 950 | DTI autoptx MD slf r tract | GCST90385242 | 8.20 |
| 951 | CD74/NPDC1 ratio | GCST90313895 | 8.19 |
| 952 | Omega-3 fatty acid levels | GCST90502422 | 8.17 |
| 953 | EDAR/SNAP23 ratio | GCST90314587 | 8.16 |
| 954 | HBEGF levels | GCST90469433 | 8.15 |
| 955 | PLXNA4/SRPK2 ratio | GCST90315688 | 8.14 |
| 956 | ZNRD2 levels | GCST90471103 | 8.13 |
| 957 | CXCL9 levels | GCST90274784 | 8.12 |
| 958 | TNFSF13B levels | GCST90470920 | 8.12 |
| 959 | Dried fruit liking | GCST90094756 | 8.11 |
| 960 | CDC27 levels | GCST90468664 | 8.06 |
| 961 | CCN2/ENO2 ratio | GCST90313712 | 8.05 |
| 962 | CCL5/SELP ratio | GCST90313705 | 8.04 |
| 963 | N-acetyl-1-methylhistidine levels | GCST90200690 | 8.04 |
| 964 | Aplastic anemia (PheCode 284) | GCST90475783 | 8.03 |
| 965 | Mineral and other dietary supplements - Zinc | Medication | UKBB00000476 | 8.03 |
| 966 | ADD1 levels | GCST90468233 | 8.02 |
| 967 | SLITRK2 levels | GCST90470670 | 8.02 |
| 968 | Never eat sugar vs no sugar restrictions (UKB data field 6144) | GCST90132934 | 8.01 |
| 969 | RNASE3 levels | GCST90470477 | 8.01 |
| 970 | Methionine sulfone levels | GCST90199961 | 8.00 |
| 971 | TP53BP1 levels | GCST90470936 | 8.00 |
| 972 | PRG2 levels | GCST90470322 | 8.00 |
| 973 | PADI4 levels | GCST90470143 | 7.99 |
| 974 | PLAUR levels | GCST90012051 | 7.98 |
| 975 | ADH4/CA5A ratio | GCST90313189 | 7.97 |
| 976 | Hepatic cancer | GCST90018638 | 7.97 |
| 977 | Left-hemisphere dorsal attention network to putamen white-matter structural connectivity | GCST90302703 | 7.97 |
| 978 | KLRB1/KLRD1 ratio | GCST90315260 | 7.97 |
| 979 | APEX1 levels | GCST90468329 | 7.96 |
| 980 | ICD10 O13: Gestational hypertension | GCST90454232 | 7.96 |
| 981 | Scar conditions and fibrosis of skin (PheCode 701.2) | GCST90476198 | 7.95 |
| 982 | PDGFB levels | GCST90470189 | 7.94 |
| 983 | DAPP1/ITGB1BP2 ratio | GCST90314388 | 7.93 |
| 984 | Dermatitis | FING00000401 | 7.92 |
| 985 | Blood cell traits latent factor 22 (white cell) | GCST90559264 | 7.92 |
| 986 | CCL5/TACC3 ratio | GCST90313707 | 7.92 |
| 987 | TIMP3 levels | GCST90470871 | 7.90 |
| 988 | Viral warts & HPV (PheCode 78) | GCST90475555 | 7.90 |
| 989 | Principal component-derived dietary pattern 42 | GCST90133047 | 7.88 |
| 990 | IDP dMRI TBSS L1 Posterior limb of internal capsule R | GCST90004093 | 7.86 |
| 991 | UROD levels | GCST90471016 | 7.86 |
| 992 | LAMA4/PDGFB ratio | GCST90315273 | 7.86 |
| 993 | CLEC1B/HBEGF ratio | GCST90314092 | 7.85 |
| 994 | TTN levels | GCST90470984 | 7.84 |
| 995 | DTI TBSS MD Cingulum cingulate gyrus R | GCST90384606 | 7.84 |
| 996 | IDP dMRI TBSS L3 Posterior limb of internal capsule R | GCST90004189 | 7.83 |
| 997 | IDP T1 FAST ROIs V cerebellum VIIIb | GCST90002582 | 7.82 |
| 998 | FUT8 levels | GCST90469281 | 7.81 |
| 999 | TSC1 levels | GCST90470972 | 7.81 |
| 1000 | FYN levels | GCST90243200 | 7.80 |